SCHEMBL24252938

SCHEMBL24252938

COc1cc(Br)cc(N)c1C(C)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 2/20 0.46
MAPK1 P28482 2/20 0.46
USP2 O75604 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.41
POLB P06746 1/20 0.41
ERN1 O75460 1/20 0.41
HTT P42858 3/20 0.40
LMNA P02545 2/20 0.40
ALDH1A1 P00352 2/20 0.40
PIM1 P11309 1/20 0.40
KDM4E B2RXH2 1/20 0.40
KMT2A Q03164 1/20 0.39
APP P05067 1/20 0.38
ALOX15 P16050 1/20 0.38
ALOX12 P18054 1/20 0.38
GAA P10253 1/20 0.37
LCK P06239 1/20 0.37
FYN P06241 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23327352 0.87 CYP3A4 (0.53) CYP3A4MAPK1USP2SMN1; SMN2ERN1
SCHEMBL14710221 0.81 CYP3A4 (0.49) CYP3A4MAPK1USP2SMN1; SMN2ERN1
SCHEMBL15462101 0.80 CYP3A4 (0.51) CYP3A4MAPK1USP2SMN1; SMN2L3MBTL1
SCHEMBL23327308 0.80 CYP3A4 (0.66) CYP3A4MAPK1USP2SMN1; SMN2POLB
SCHEMBL30016451 0.80 CYP3A4 (0.66) CYP3A4MAPK1USP2SMN1; SMN2POLB
SCHEMBL2203125 0.80 CYP3A4 (0.66) CYP3A4MAPK1USP2SMN1; SMN2L3MBTL1
SCHEMBL18622413 0.79 MAPK1 (0.46) CYP3A4MAPK1USP2SMN1; SMN2L3MBTL1
SCHEMBL23589220 0.77 THRB (0.39) CYP3A4MAPK1ERN1HTTALDH1A1
SCHEMBL17565225 0.76 HTT (0.47) CYP3A4SMN1; SMN2POLBERN1HTT
SCHEMBL24252949 0.76 THRB (0.45) CYP3A4MAPK1HTTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
CN-116947903-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-10-27 CN disclosed
CN-116261564-A Inhibitors of complement factors and uses thereof 安尼艾克松股份有限公司 2023-06-13 CN disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP3A4 2694/4885MAPK1 2160/4885USP2 4226/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 CYP3A4 2694/4885MAPK1 2160/4885USP2 4226/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 CYP3A4 2694/4885MAPK1 2160/4885USP2 4226/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 CYP3A4 3719/4885MAPK1 2554/4885USP2 3122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.